National Research NRC Q4 2025 Earnings Transcript

National Research reported Q4 revenue of $35.2 million, down 5% year over year but up 2% sequentially, while TRCV rose 8% to $144.1 million, marking the fifth straight quarter of sequential growth. Full-year adjusted EBITDA was $40.2 million, a 29% margin, with 99% recurring revenue, 86% growth in new sales, and a quarterly dividend of $0.12 per share. Management said revenue should follow TRCV into 2026 and highlighted AI feature rollouts, Rounding momentum, and leadership additions as growth drivers.

Analysis

NRC’s real story is not the headline revenue decline; it’s that the company is exiting a reset phase with a cleaner demand funnel and a larger deferred-revenue engine. The 8% TRCV growth matters more than current bookings because it likely gives 2-3 quarters of visible acceleration into reported revenue, which should mechanically lever margins if the sales mix holds. The market is probably underweighting how much of the current base is now insulated by the near-complete recurring mix, making downside from cyclical budgeting far less severe than in a typical healthcare software name.

The more interesting second-order effect is competitive: by embedding Rounding and AI listening into a broader workflow stack, NRC is moving from “measurement vendor” to “operational control point.” That raises switching costs and can compress decision cycles across adjacent modules, which should help cross-sell but also makes the company more vulnerable to execution slippage if product adoption stalls; this is a land-grab dynamic, not a steady-state annuity. If the go-to-market restructure continues to improve average deal size, smaller point-solution vendors in patient experience and rounding workflows will feel the squeeze first, especially those without a board-level governance angle.

The main risk is that 2026 expectations get ahead of actual revenue realization: TRCV can keep compounding while reported sales lag if implementation cycles lengthen or if health systems delay conversion to preserve budgets. A less obvious risk is that the new AI features could be seen as incremental rather than differentiated, forcing NRC to spend more on product and customer success to defend retention. The setup is favorable over 6-12 months, but the next two quarters will likely be judged on whether TRCV converts to visible topline inflection, not on margin durability alone.

Key Decisions for Investors

• Long NRC on a 6-12 month horizon; favor entry on post-print weakness if the market fixates on lagging revenue rather than TRCV conversion. Risk/reward: attractive if TRCV translates into mid-teens reported growth by late 2026; downside is limited by recurring revenue durability and capital return.
• Pair trade: long NRC / short a basket of smaller healthcare workflow point-solution vendors with weaker retention and no recurring-contract visibility over the next 2-3 quarters. Thesis: integrated workflow platforms with board-level relationships should capture incremental wallet share first.
• Sell near-dated out-of-the-money puts on NRC only if implied vol spikes after a weak revenue-print narrative. The credit should monetize the gap between visible TRCV momentum and market impatience, with assignment acceptable if you want a higher-conviction entry.
• If holding a healthcare software basket, rotate a portion from slower-growth names into NRC for the next 2 reporting cycles. NRC offers a cleaner path to EBITDA margin expansion plus dividend support, giving better downside protection than most early-cycle software peers.
• Avoid chasing after a strong gap-up unless management confirms conversion timing on the next call. The key risk/reward inflection is the first evidence of revenue re-acceleration, not the existence of TRCV growth alone.